Advance of radioiodine antagonist related gene of differentiated thyroid carcinoma / 国际肿瘤学杂志

ABSTRACT

Thyroid carcinomas are the most common endocrine malignancies,and the overwhelming majority of them is differentiated thyroid carcinoma (DTC).The major therapies of DTCs are surgical resection,thyroid stimulating hormone (TSH) inhibitory treatment and iodine radioisotope (131I) treatment.131I has been widely applied for the diagnosis and treatment of DTC,however,part of these patients may reduce or loss the uptake capacity of 131I owing to the alteration of sodium-iodide symporter gene,BRAF,paired box 8,microRNA and cytokeratin 19.These genes are particularly important in the treatment of DTC,which can be used as biomarkers in the treatment efficacy evaluation.